Chinese biopharmas invest in the future of home-grown biologics, biosimilars

HONG KONG – Chinese biopharmaceutical companies are upping the ante in the development of biological drugs and biosimilars of existing best sellers, many of them looking to capitalize on the huge domestic market.

To continue reading subscribe now to BioWorld Asia (formerly International)